Dual RAS blockade - Controversy resolved

Nature Reviews Nephrology

Volumn 9, Issue 11, 2013, Pages 640-

  Ruggenenti, Piero ^a   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OLMESARTAN; RENIN INHIBITOR; SPIRONOLACTONE;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DIABETIC PATIENT; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; KIDNEY FAILURE; LETTER; META ANALYSIS (TOPIC); PATIENT COUNSELING; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; DRUG EFFECT; FEMALE; MALE; NOTE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; MALE; RENIN-ANGIOTENSIN SYSTEM;

EID: 84890806222     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.82-c2     Document Type: Letter

References (16)

1. Ruggenenti, P. & Remuzzi, G. Renin-angiotensin system: Meta-analyses can misdirect decisions on treatment. Nat. Rev. Nephrol. 9, 311-312 (2013).
2. Makani, H., Bangalore, S., Desouza, K.A., Shah, A. & Messerli, F.H. Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials. BMJ 346, f360 (2013).
3. Makani, H. et al. Dual RAS blockade-unresolved controversy. Nat. Rev. Nephrol. http://dx.doi.org/10.1038/nrneph.2013.82-c1.
4. Parving, H.H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204-2213 (2012).
5. US Department of Health and Human Services. Aliskiren-containing medications: Drug safety comunication-new warning and contraindication. US Food and Drug Administration [online], http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm301120.htm (2012).
6. Noris, M. & Remuzzi, G. Thrombotic microangiopathy: What not to learn from a meta-analysis. Nat. Rev. Nephrol. 5, 186-188 (2009).\
7. Gay, J. Clinical epidemiology & evidence-based medicine glossary: Clinical study design and methods terminology. Washington State University College of Veterinary Medicine [online], http://www.vetmed.wsu.edu/courses- jmgay/GlossClinStudy.htm (2010).
8. Ruggenenti, P. et al. Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213-1224 (2008).
9. Remission Clinic Task Force. The Remission Clinic approach to halt the progression of kidney disease. J. Nephrol. 24, 274-281 (2011).
10. US Department of Health and Human Services. FDA Drug Safety Communication: Safety review update of benicar (olmesartan) and cardiovascular events. US Food and Drug Administration [online], http://www.fda.gov/Drugs/ DrugSafety/ucm251268.htm (2011).
11. Ruggenenti, P. & Remuzzi, G. Kidney failure stabilizes after a two-decade increase: Impact on global (renal and cardiovascular) health. Clin. J. Am. Soc. Nephrol. 2, 146-150 (2007).
12. Ruggenenti, P. et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352, 1252-1256 (1998).
13. de Zeeuw, D. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 65, 2309-2320 (2004).
14. Ruggenenti, P., Perna, A. & Remuzzi, G. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int. 63, 2254-2261 (2003).
15. Ruggenenti, P., Schieppati, A. & Remuzzi, G. Progression, remission, regression of chronic renal diseases. Lancet 357, 1601-1608 (2001).
16. Cravedi, P., Ruggenenti, P. & Remuzzi, G. Proteinuria should be used as a surrogate in CKD. Nat. Rev. Nephrol. 8, 301-306 (2012).